Level 3 Heart Disease Testing
9p21 Genotype: This test determines the risk levels for certain types of heart disease. If you are a9p21 carrier, you may have a higher risk of a heart attack before the age of 60 if you are female and age 50 if you are male or abdominal aortic aneurysm, blocked coronary arteries, or a heart attack at any age.
Microalbumin: This test detects the levels of the very small (micro) elevations of albumin in your urine. Albumin is a protein normally found in your blood, but not normally in urine. If microalbumin is present in your urine, it may signify that your kidneys and arteries are damaged. Your doctor may want to check your microalbumin level if you have heart attack risk factors: smoking, high blood pressure, high blood sugar, or high cholesterol levels.
KIF6 Genotype: People who carry the KIF6 gene may have higher risk of heart disease events. (such as heart attacks)
CYP2C19: The CYP2C19 Genotype test evaluates how well your body processes the medication clopidogrel (Plavix). If you are a poor or intermediate metabolizer, Plavix may be less effective at preventing blood clots.
LPA-Aspirin Genotype: This test can give insight into your risk of heart disease, as well as your response to aspirin. If you are an LPA- aspirin carrier, you may have higher risk of heart disease events (such as heart attack). However, low-dose aspirin may help reduce your risk.
4q25-AF: The 4q25-AF Genotype test evaluates your risk of atrial fibrillation (AF [irregular heartbeat]) and your risk of stroke caused by AF. If you are a 4q25-AF carrier, you may have a higher risk of AF and stroke caused by AF.
LPA-Intron 25 Genotype: If you are an LPA-Intron 25 carrier, you may have a higher risk of heart disease.
ApoE Genotype: The Apo-E Genotype test assesses your risk of heart disease, as well as your response to different amounts of dietary fats. There are six Apo-E genotypes. If you have 3⁄4 or 4/4 genotype, you may have a higher risk of heart disease.
Prevencio HART CVE Test: This is a highly accurate, simple blood test which helps detect your 1-year risk for heart attack, stroke, or cardiac death- the #1 cause of death in the United States. Researchers used artificial intelligence to select important heart proteins and combine them into a scoring system to provide each patient with their own risk score. HART CVE proved to be more accurate (86%) than other available tests, including genetic and coronary artery calcium scores (60%). We will receive your HART results in 2 weeks and will personalize a treatment plan for you based on the risk category identified. We may prescribe new supplements or medications or adjust these to address cholesterol or high blood pressure, prescribe a new nutrition plan for you, suggest additional heart tests to learn more about your heart, and check improvements or changes in your heart by monitoring the HART CVE test once or twice a year.
Cleerly CT: Cleerly allows for the identification and quantification of all forms of plaque. Although the heart saver CT can detect and quantify atherosclerosis and is valuable in informing treatment decisions in asymptomatic adults, this scan cannot detect and quantify low-density, non-calcified unstable plaque which is more likely than the hardened and calcified plaque seen on the heart saver CT’s to rupture and cause a blood clot to form. Simply put, a heart saver CT score of zero does not exclude the presence of high-risk plaque. Cleerly’s model of personalized cardiovascular care leverages the AI-enabled analysis of coronary computed tomography angiography (CCTA) images to identify, characterize, and quantify plaque buildup. Several studies have concluded that CCTA shows coronary atherosclerosis in 41% to 53% of patients with a heart saver CT score of zero. The Western Denmark Health Study further found that 31% of major adverse cardiac events occur in patients with a heart saver CT score of zero.
The healthcare system misses more than half of patients who appear to be the picture of health but suffer a heart attack because they have a buildup of non-calcified plaque that a traditional heart saver CT scan misses. Cleerly identifies patients at a high risk of coronary artery disease sooner than the traditional heart saver CT scan. This can help physicians prevent heart attacks and reduce the number of preventable but costly hospitalizations and readmissions that healthcare organizations experience every year.